FibroGen Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
20 avr. 2022 07h00 HE
|
FibroGen, Inc.
- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
Antisense Therapeutics to present poster at world’s largest NMD conference
09 mars 2022 15h01 HE
|
Antisense Therapeutics Limited
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular...
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
14 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
04 févr. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...
FibroGen to Report Third Quarter 2021 Financial Results
26 oct. 2021 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will...
FibroGen to Present at Upcoming Investor Conferences
27 mai 2021 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen to Report First Quarter 2021 Financial Results
03 mai 2021 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
FibroGen to Present at Upcoming Investor Conference
28 avr. 2021 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...